BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36822077)

  • 21. Clonal hematopoiesis and associated diseases: A review of recent findings.
    Asada S; Kitamura T
    Cancer Sci; 2021 Oct; 112(10):3962-3971. PubMed ID: 34328684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clonal hematopoiesis: a risk factor for leukemia and cardiovascular disease?].
    van Zeventer IA; Buisman SC; de Graaf AO; de Haan G; Jansen JH; Huls G
    Ned Tijdschr Geneeskd; 2020 Nov; 164():. PubMed ID: 33331716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
    Hanfstein B; Müller MC; Kreil S; Ernst T; Schenk T; Lorentz C; Schwindel U; Leitner A; Hehlmann R; Hochhaus A
    Haematologica; 2011 Mar; 96(3):360-6. PubMed ID: 21134983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Forced expression of Wnt antagonists sFRP1 and WIF1 sensitizes chronic myeloid leukemia cells to tyrosine kinase inhibitors.
    Pehlivan M; Caliskan C; Yuce Z; Sercan HO
    Tumour Biol; 2017 May; 39(5):1010428317701654. PubMed ID: 28468589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal hematopoiesis and cardiovascular disease: deciphering interconnections.
    Stein A; Metzeler K; Kubasch AS; Rommel KP; Desch S; Buettner P; Rosolowski M; Cross M; Platzbecker U; Thiele H
    Basic Res Cardiol; 2022 Nov; 117(1):55. PubMed ID: 36355225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal Hematopoiesis and risk of Acute Myeloid Leukemia.
    Desai P; Hassane D; Roboz GJ
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):177-185. PubMed ID: 31203999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clonal hematopoiesis: causes and clinical implications].
    Burchert A
    Z Gerontol Geriatr; 2023 Feb; 56(1):65-72. PubMed ID: 36662242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
    J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F.
    Misaka T; Kimishima Y; Yokokawa T; Ikeda K; Takeishi Y
    J Cardiol; 2023 Jan; 81(1):3-9. PubMed ID: 35165011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
    Williams RT; Sherr CJ
    Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation.
    Grimm J; Bill M; Jentzsch M; Beinicke S; Häntschel J; Goldmann K; Schulz J; Cross M; Franke GN; Behre G; Vucinic V; Pönisch W; Lange T; Niederwieser D; Schwind S
    Bone Marrow Transplant; 2019 Aug; 54(8):1189-1197. PubMed ID: 30504903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal Hematopoiesis and therapy related MDS/AML.
    Desai P; Roboz GJ
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
    Miyazaki S
    Rinsho Ketsueki; 2021; 62(8):1024-1028. PubMed ID: 34497188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
    Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C
    Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic].
    Ziemann F; Metzeler KH
    Dtsch Med Wochenschr; 2023 Apr; 148(8):441-450. PubMed ID: 36990116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.
    Jahn J; Diamond B; Hsu J; Montoya S; Totiger TM; Landgren O; Maura F; Taylor J
    Leuk Res; 2023 Mar; 126():107020. PubMed ID: 36696829
    [TBL] [Abstract][Full Text] [Related]  

  • 38. c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
    Rosti V; Bergamaschi G; Ponchio L; Cazzola M
    Leukemia; 1992 Jan; 6(1):1-7. PubMed ID: 1736009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
    Etienne G; Dulucq S; Huguet F; Schmitt A; Lascaux A; Hayette S; Fort MP; Sujobert P; Bijou F; Morisset S; Tavitian S; Bidet A; Turcq B; Robbesyn F; Chollet C; Belloc F; Durrieu F; Mahon FX; Nicolini FE
    Cancer Med; 2019 Sep; 8(11):5173-5182. PubMed ID: 31350815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis.
    Menendez-Gonzalez JB; Rodrigues NP
    Methods Mol Biol; 2022; 2419():73-88. PubMed ID: 35237959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.